

Appl. No. 09/623,138  
Amdt. dated July 31, 2003  
Reply to Office action of April 3, 2003

Amendments to the Claims

This listing of claims will replace all prior versions,  
and listings, of claims in the application.

Listing of Claims:

Claims 1-10 (canceled).

Gl  
Claim 11 (currently amended) A method for  
inhibiting ocular Langerhans cell migration in a mammal  
comprising administering an effective amount of a  
Langerhans cell migration inhibitor comprising a compound  
selected from calcitriol; 1 $\alpha$ ,24-dihydroxy vitamin D<sub>3</sub>;  $\alpha$ -  
calcidol; calcifedol; 1 $\alpha$ , 25,26-trihydroxy vitamin D<sub>3</sub>;  
1 $\beta$ ,25-dihydroxy vitamin D<sub>3</sub>; 24-homo-1 $\alpha$ ,25-dihydroxy  
vitamin D<sub>3</sub>; 26-homo-1 $\alpha$ ,25-dihydroxy vitamin D<sub>3</sub>; 22-  
oxacalcitol; and calcipotriol as an active ingredient to  
the mammal, wherein the inhibition of said ocular  
Langerhans cell migration results in the ~~prevention or~~  
treatment of keratoconjunctivitis, phlyctenular  
keratitis, or corneal infiltration and wherein the  
compounds treat the ocular inflammation without lowering  
transparency of the cornea.

Claims 12-13 (canceled).

Appl. No. 09/623,138  
Amdt. dated July 31, 2003  
Reply to Office action of April 3, 2003

Claim 14 (previously presented) The method of  
Claim 11 wherein the compound is calcitriol or 22-  
oxacalcitriol.

61  
G  
Cont  
Claim 15 (previously presented) The method of  
Claim 14 wherein the inhibitor is in the form of an  
ophthalmic solution.

Claim 16 (canceled)

Claim 17 (currently amended) The method of  
Claim 15 wherein the inhibition of the Langerhans cell  
migration results in the ~~prevention of~~ treatment of  
keratoconjunctivitis.

Claim 18 (canceled).

Claim 19 (previously presented) The method of  
Claim 15 wherein the inhibition of the Langerhans cell  
migration results in the prevention or treatment of  
phlyctenular keratitis or corneal infiltration.

Claim 20 (currently amended) The method of  
Claim 15 wherein the inhibitor prevents and/or treats an  
ocular inflammation wherein the inhibition of the

Appl. No. 09/625,138

Amdt. dated July 31, 2003

Reply to Office action of April 3, 2003

*Gr  
cont*

Langerhans cell migration results in the ~~prevention or~~  
treatment of an ocular inflammation by inhibiting the  
production of interleukin-1 in corneal epithelial  
cells.

---